2929417-90-1
Chemical Structure
AST5902 trimesylate
- CAS No.: 2929417-90-1
- Formula:C30H41F3N8O11S3
- Molecular Weight:842.88
IUPAC Name: N-(2-(methyl(2-(methylamino)ethyl)amino)-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)acrylamide trimethanesulfonate
InChIKey: KRCDPFVVSHJNOV-UHFFFAOYSA-N
SMILES: CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(C)CCNC)=O.CS(=O)(O)=O.CS(=O)(O)=O
Biological Activity: AST5902 trimesylate is the active metabolite of Furmonertinib (HY-112870) with antitumor activity, and acts as a EGFR inhibitor. AST5902 trimesylate inhibits CYP3A4 mRNA transcription at low concentrations and induces CYP3A4 mRNA expression at high concentrations. AST5902 trimesylate can be used in research related to non-small cell lung cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AST5902 trimesylate | 98.75% | AST5902 trimesylate is the active metabolite of Furmonertinib (HY-112870) with antitumor activity, and acts as a EGFR inhibitor. AST5902 trimesylate inhibits CYP3A4 mRNA transcription at low concentrations and induces CYP3A4 mRNA expression at high concentrations. AST5902 trimesylate can be used in research related to non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AST5902 trimesylate (Standard) | ≥98% | AST5902 trimesylate (Standard) is the analytical standard of AST5902 trimesylate (HY-138627A). This product is intended for research and analytical applications. AST5902 trimesylate is the active metabolite of Furmonertinib (HY-112870) with antitumor activity, and acts as a EGFR inhibitor. AST5902 trimesylate inhibits CYP3A4 mRNA transcription at low concentrations and induces CYP3A4 mRNA expression at high concentrations. AST5902 trimesylate can be used in research related to non-small cell lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zou HX, et al. Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. Acta pharmacologica Sinica. 2022 Jul;43(7):1865-1874.
- [2]. Liu XY, et al. Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta pharmacologica Sinica. 2020 Oct;41(10):1366-1376. [Content Brief]
